Back to News
Market Impact: 0.25
Amgen's Real-World Data Shows Repatha Outperforms Ezetimibe For Heart Disease
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Amgen announced results from a large real-world study indicating that Repatha (evolocumab) reduced the risk of fatal or nonfatal heart attacks among people with atherosclerotic cardiovascular disease who had previously used statins. The report provided no numerical effect size or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
AMGN0.70
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook